Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KHN922
- Development stage
- Phase 2
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KHN922 is a dual-payload antibody-drug conjugate (ADC) developed by Chengdu Kanghong Biotech Co., Ltd. for the treatment of advanced solid tumors. It specifically targets the human epidermal growth factor receptor 3 (HER3). Unlike traditional ADCs that utilize a single cytotoxic agent, KHN922 features a dual-payload system consisting of a topoisomerase 1 inhibitor and an RNA polymerase 2 inhibitor. This innovative approach aims to overcome resistance mechanisms and enhance anti-tumor efficacy by simultaneously disrupting DNA replication and transcription within cancer cells. The drug is currently undergoing Phase 1/2 clinical evaluation to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced malignancies.
- Other names
- KHN922 for injectionKHN-922 for injectionKHN 922 for injection
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)Pol II (RNA polymerase II elongation factors)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on KHN922.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KHN922.